# UnitedHealth Group Incorporated Common Stock (DE) (UNH) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Providers & Services. Price $397.14, market value $356.5 billion.

## Valuation
- **P/E (trailing): 25.5×** (5-yr avg 25.2×, 3-yr avg 25.6×). UnitedHealth Group Incorporated Common Stock (DE) trades at 25.5× trailing earnings, close to its own five-year average of 25.2×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.7×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.8×**. Each dollar of revenue is priced at 0.8×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 3.7×**. The shares trade at 3.7× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.8×**. Enterprise value is 15.8× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 6.6%** (5-yr avg 5.0%). Free cash flow equals 6.6% of the market value, above its five-year average of 5.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 3.9%**. The inverse of the P/E: 3.9% of the price is earned each year.

## Profitability
- **Operating margin: 4.8%**. 4.8% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 2.7%**. 2.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.0%**. 12.0% on shareholders' equity is solid.
- **Return on invested capital: 11.1%**. Return on all capital, debt included, is 11.1%.
- **Return on assets: 4.6%**. Each dollar of assets produces 4.6% of profit.

## Growth
- **Revenue growth (1 yr): 11.8%** (3-yr 11.4%/yr, 5-yr 11.7%/yr). Revenue grew 11.8% over the last year, against 11.7% a year compounded over five years.
- **EPS growth (1 yr): -14.7%** (3-yr -14.5%/yr, 5-yr -3.8%/yr). Earnings per share fell 14.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -11.8%/yr**. Free cash flow has compounded at -11.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.78**. Debt is 0.78 times equity, moderate leverage.
- **Net debt / EBITDA: 2.1×**. It would take 2.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 3.13**. A Z-score of 3.13 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.34%** ($8.95 per share, trailing). UnitedHealth Group Incorporated Common Stock (DE) yields 2.34%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 66%** (34% of free cash flow). 66% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 12.6%/yr** (1-yr 6.7%). The dividend has compounded at 12.6% a year over five years, doubling roughly every 6 years at that pace.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover UnitedHealth Group Incorporated Common Stock (DE); the consensus is buy, with an average price target of $475.23 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 31.4%** (YTD 21.9%, 3-mo -0.0%). The shares are up 31.4% over twelve months including dividends.
- **From 52-week high: -14.0%** (55.2% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.44** (volatility 35%). Beta of 0.44 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=UNH · Page: https://foliofundamentals.com/stocks/unh

Not investment advice.